title: Treatment of Benign Prostatic Hyperplasia by Ultrasound-Guided Botulinum Toxin Type A Injection.
abstract: The objective of the study was to determine the efficacy of ultrasound-guided botulinum toxin type A (BTX-A) injection in the treatment of benign prostatic hyperplasia (BPH). In the 32 patients clinically diagnosed with BPH, 200 IU BTX-A was injected into five points at the lateral and middle lobes of the prostate under the guidance of ultrasound using a balloon dilatational device. The international prostate symptom score, quality of life score, maximum flow rate, post-void residual urine volume, prostate-specific antigen, and prostate volume were determined before treatment and at 1, 3, 6, and 12 months after treatment. All clinical symptoms and indicators were remarkably improved 1 month after the treatment and reached the optimal levels at 6 months post-treatment. This improvement of clinical parameters was maintained for a period of at least 1 year. Ultrasound-guided BTX-A injection was found to be safe and effective in the management of BPH.
authors.affiliation: Department of Rehabilitation, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China.
authors.forename: Xu-Dong
authors.initials: XD
authors.lastname: Ding
authors.affiliation: Department of Rehabilitation, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China.
authors.forename: Huan-Xian
authors.initials: HX
authors.lastname: Chen
authors.affiliation: Department of Rehabilitation, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China.
authors.forename: Hong-Qiong
authors.initials: HQ
authors.lastname: Xiao
authors.affiliation: Department of Rehabilitation, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Rehabilitation, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China.
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: Ding
authors.affiliation: Department of Rehabilitation, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China.
authors.forename: Gui-Bin
authors.initials: GB
authors.lastname: Zhang
authors.affiliation: Department of Rehabilitation, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China. dingxd1018@163.com.
authors.forename: Du-Guan
authors.initials: DG
authors.lastname: Fu
mesh_terms: D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011788:Quality of Life; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D017430:Prostate-Specific Antigen; D019274:Botulinum Toxins, Type A
keywords: Benign prostatic hyperplasia; Botulinum toxin type A; Ultrasound-guided therapy